Figure 1.
Phenotypic analysis of LDGs and NDGs.
LDGs and NDGs were isolated as described in materials and methods (n = 7) and the expression levels of arginase, CD66b, CD15, CD63, CD33 and CD16 were determined by flow cytometry. Statistical significance was determined by a two-tailed Mann-Whitney test. Box = interquartile range and median; whiskers = range.
Table 1.
Expression levels of arginase and phenotypic markers of NDGs and LDGs in cord blood.
Table 2.
Expression levels of arginase and phenotypic markers of NDGs and LDGs in maternal peripheral blood.
Figure 2.
Comparison of the phenotype of LDGs in neonate and maternal blood and placentae.
LDGs were isolated as described in materials and methods (n = 7) and the expression levels of CD66b was determined by flow cytometry. Statistical significance was determined by a kruskal-Wallis test. Box = interquartile range and median; whiskers = range.
Table 3.
Comparison of expression levels of arginase and phenotypic markers of LDGs in placentae, cord and maternal blood.
Table 4.
Comparison of expression levels of arginase and phenotypic markers of NDGs in placentae, cord and maternal blood.
Figure 3.
Percentage of LDGs in neonatal and maternal blood and placentae.
LDGs were isolated as described in materials and methods (n = 7) and the percentage of CD15+ arginase+ cells was determined by flow cytometry. The percentage of LDGs present in the peripheral blood of healthy controls was 0.24±0.3 [12] Statistical significance was determined by a kruskal-Wallis test. Box = interquartile range and median; whiskers = range.
Table 5.
Percent of Arginase1+CD15+ LDGs present in placentae, cord blood and maternal blood.